Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
44.4(c) 44.96(c) 44.22(c) 44.78(c) 45.82(c) Last
104 145 34 016 48 733 64 519 52 544 Volume
-2.84% +1.26% -1.65% +1.27% +2.32% Change
More quotes
Estimated financial data (e)
Sales 2021 136 M 147 M 147 M
Net income 2021 -21,5 M -23,2 M -23,2 M
Net Debt 2021 82,2 M 88,7 M 88,7 M
P/E ratio 2021 -22,1x
Yield 2021 -
Sales 2022 151 M 163 M 163 M
Net income 2022 -30,9 M -33,4 M -33,4 M
Net Debt 2022 36,2 M 39,0 M 39,0 M
P/E ratio 2022 -18,7x
Yield 2022 -
Capitalization 541 M 584 M 583 M
EV / Sales 2021 4,56x
EV / Sales 2022 3,83x
Nbr of Employees 160
Free-Float 88,5%
More Financials
Company
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The... 
More about the company
Ratings of Basilea Pharmaceutica AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about BASILEA PHARMACEUTICA AG
09/17BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage..
MT
09/17PRESS RELEASE : Basilea presents full safety and -2-
DJ
09/17Basilea presents full safety and efficacy data set on derazantinib in patients with FGF..
DJ
09/17PRESS RELEASE : Basilea presents full safety and efficacy data set on derazantinib in pati..
DJ
09/17Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib i..
CI
08/17Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/17PRESS RELEASE : Basilea reports strong financial -3-
DJ
08/17PRESS RELEASE : Basilea reports strong financial results for half-year 2021 with significa..
DJ
08/17PRESS RELEASE : Basilea reports strong financial -2-
DJ
08/17BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with significa..
AQ
08/17Basilea Pharmaceutica AG Provides Earnings Guidance for the Full Year 2021
CI
08/16BASILEA PHARMACEUTICA : Wins Additional $4.3 Million US Funding to Develop Antibiotic
MT
08/16Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of c..
DJ
08/16PRESS RELEASE : Basilea awarded additional USD 4.3 million by BARDA to support phase 3 dev..
DJ
07/29BASILEA PHARMACEUTICA : Gets US FDA's Orphan Drug Designation For Brain Cancer Treatment
MT
More news
News in other languages on BASILEA PHARMACEUTICA AG
09/17BASILEA : durée de vie prolongée avec dérazantinib
09/17Basilea präsentiert neue Daten zur Lebenserwartung bei Derazantinib-Therapie
09/17Les résultats actualisés d'une étude de mi-parcours montrent que l'efficacité du médica..
09/17GlobeNewswire/Basilea präsentiert auf -2-
09/17GlobeNewswire/Basilea präsentiert auf ESMO-Kongress vollständige Daten zur Sicherheit u..
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 45,82 CHF
Average target price 87,60 CHF
Spread / Average Target 91,2%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Chief Financial Officer
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-13.79%584
MODERNA, INC.291.35%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.38.49%50 128
CELLTRION, INC.-25.49%31 745
SEAGEN INC.-7.21%29 353